Pfizer (PFE)

24.27
+0.39 (1.63%)
NYSE· Last Trade: Jul 2nd, 4:09 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.fool.com
Analysts have given Alnylam Pharmaceuticals an average price target of $436.
Via The Motley Fool · July 2, 2026
2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Turn Down
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Via StockStory · July 2, 2026
Pfizer vs Verizon Communications: Which High-Yielding Dividend Stock Is the Better Buy?fool.com
These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals.
Via The Motley Fool · July 1, 2026
Most active S&P500 stocks in Wednesday's sessionchartmill.com
Via Chartmill · June 24, 2026
Branded Pharmaceuticals Stocks Q1 Teardown: Zoetis (NYSE:ZTS) Vs The Rest
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Zoetis (NYSE:ZTS) and its pee...
Via StockStory · June 30, 2026
The Fine Print Most Canadians Miss When Holding U.S. Stocks in a TFSAhttps://www.fool.ca/2026/06/30/the-fine-print-most-canadians-miss-when-holding-u-s-stocks-in-a-tfsa/?source=iedfctemc0000001&utm_source=financialcontent&utm_campaign=CA_All_Articles&utm_content=Articles&utm_medium=rssfeed&lidx=0&referring_guid=0a3ce396-ccae-4f76-a30a-c0f42b69775c
Maximize your investment opportunities in US stocks with a TFSA while being aware of the tax implications of dividends.
Via The Motley Fool · June 30, 2026
Looking for the most active stocks in the S&P500 index on Tuesday?chartmill.com
Via Chartmill · June 30, 2026
Why Pfizer Could Prove to Be an Underrated GLP-1 Stockfool.com
It could prove to be a case of better later than never for the healthcare giant.
Via The Motley Fool · June 30, 2026
Big Pharma Has a Case of Merger Maniafool.com
Pharmaceutical companies are on an M&A spree that could break records this year as they look for novel drug and clinical-stage candidates to bolster the development pipeline.
Via The Motley Fool · June 30, 2026
Nike Just Hit an 11-Year Low. Will Its Turnaround Finally Start on Wednesday?fool.com
Nike is set to report earnings on June 30. Here's what to expect.
Via The Motley Fool · June 30, 2026
3 No-Brainer Dividend Stocks to Buy Right Nowfool.com
AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.
Via The Motley Fool · June 29, 2026
3 Monster Stocks to Buy Right Now With Dividend Yields of 5% or Morefool.com
Why settle for puny yields when you can buy these monster dividend stocks?
Via The Motley Fool · June 29, 2026
A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?fool.com
Things are going from bad to worse for the pharmaceutical giant.
Via The Motley Fool · June 28, 2026
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Nowfool.com
Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.
Via The Motley Fool · June 27, 2026
The Market Just Pulled Back Again. These 3 Blue Chips Are the Ones to Buy.fool.com
Take advantage of short-term weakness by stepping into the right long-term investments when they go on sale.
Via The Motley Fool · June 27, 2026
Here's How Many Shares of Pfizer You Must Own to Get $5,000 in Yearly Dividendsfool.com
The sizable yield comes with a concerning footnote. Just look at the rest of the story.
Via The Motley Fool · June 27, 2026
Alphabet Is Joining the Dow Jones Industrial Average. 3 Surprising Reasons Why SpaceX Could Be Next.fool.com
With just 30 components, the Dow's exclusivity is built on industry leadership, which SpaceX has in spades.
Via The Motley Fool · June 27, 2026
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?fool.com
AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.
Via The Motley Fool · June 25, 2026
An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?fool.com
Novo Nordisk is no longer the front-runner, but it's not out of the running, either.
Via The Motley Fool · June 25, 2026
FDA Expands Pfizer's Ibrance Label For Frontline Maintenance In Advanced Breast Cancerbenzinga.com
The FDA approves Pfizer's Ibrance regimen for HR+, HER2+ metastatic breast cancer maintenance after positive Phase 3 data.
Via Benzinga · June 25, 2026
2 Large-Cap Stocks to Target This Week and 1 We Find Risky
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...
Via StockStory · June 25, 2026
The Highest Dividend Yields Are Often the Least Safe. Here's How to Tell the Difference.talkmarkets.com
Income investors are drawn to the biggest yields, but the biggest yields frequently belong to the companies the market trusts least. A yield is simply the
Via Talk Markets · June 24, 2026
Pfizer Stock Trades Flat Following Mixed Phase 3 Lung Cancer Trial Databenzinga.com
Pfizer shares are trading flat in Wednesday's premarket as traders weigh mixed Phase 3 trial headlines alongside a firmer overnight tape.
Via Benzinga · June 24, 2026
2 High-Yield Dividend Stocks to Buy and Hold for a Decadefool.com
Don't wait until they recover to initiate positions.
Via The Motley Fool · June 23, 2026
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session.chartmill.com
Via Chartmill · June 23, 2026